X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (249) 249
Publication (14) 14
Magazine Article (8) 8
Book Review (5) 5
Newsletter (4) 4
Trade Publication Article (2) 2
Book Chapter (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (159) 159
pegaptanib (146) 146
ophthalmology (136) 136
index medicus (131) 131
ranibizumab (131) 131
pegaptanib sodium (122) 122
macular degeneration (109) 109
bevacizumab (104) 104
vascular endothelial growth factor a - antagonists & inhibitors (94) 94
vascular endothelial growth factor (74) 74
aptamers, nucleotide - therapeutic use (71) 71
age-related macular degeneration (65) 65
female (63) 63
angiogenesis inhibitors - therapeutic use (62) 62
male (62) 62
endothelial growth-factor (59) 59
photodynamic therapy (54) 54
choroidal neovascularization (53) 53
macular degeneration - drug therapy (53) 53
aged (52) 52
eye diseases (46) 46
treatment outcome (43) 43
choroidal neovascularization - drug therapy (41) 41
intravitreal injections (40) 40
middle aged (38) 38
genetic structures (36) 36
visual acuity (36) 36
animals (33) 33
pharmacology & pharmacy (33) 33
antibodies, monoclonal, humanized (32) 32
aptamers, nucleotide - administration & dosage (31) 31
verteporfin (31) 31
aged, 80 and over (30) 30
care and treatment (30) 30
drug therapy (30) 30
diabetic retinopathy (29) 29
anti-vegf (28) 28
physiological aspects (28) 28
research (28) 28
diabetic macular edema (27) 27
fluorescein angiography (27) 27
angiogenesis inhibitors - administration & dosage (26) 26
angiogenesis inhibitors - adverse effects (26) 26
aptamers, nucleotide - adverse effects (26) 26
macular degeneration - complications (26) 26
neovascularization (26) 26
visual acuity - physiology (26) 26
dosage and administration (25) 25
sense organs (25) 25
triamcinolone (24) 24
vitreous body (24) 24
antibodies, monoclonal - therapeutic use (22) 22
choroidal neovascularization - etiology (22) 22
injection (22) 22
injections (22) 22
retrospective studies (22) 22
safety (22) 22
therapy (22) 22
tomography, optical coherence (22) 22
vegf (22) 22
intravitreal bevacizumab avastin (21) 21
angiogenesis (20) 20
bevacizumab avastin (20) 20
intravitreal bevacizumab (20) 20
intravitreal injection (20) 20
laser photocoagulation (19) 19
macular edema - drug therapy (19) 19
review (19) 19
clinical trials (18) 18
medicine & public health (18) 18
prospective studies (18) 18
triamcinolone acetonide (18) 18
visual acuity - drug effects (18) 18
antibodies, monoclonal, humanized - therapeutic use (17) 17
macular degeneration - physiopathology (17) 17
verteporfin photodynamic therapy (17) 17
diabetes (16) 16
diabetic retinopathy - drug therapy (16) 16
macular edema (16) 16
medicine, research & experimental (16) 16
optical coherence tomography (16) 16
subfoveal choroidal neovascularization (16) 16
wet macular degeneration - drug therapy (16) 16
analysis (15) 15
choroidal neovascularization - physiopathology (15) 15
studies (15) 15
aflibercept (14) 14
clinical ophthalmology (14) 14
macugen (14) 14
retina (14) 14
adult (13) 13
aptamer (13) 13
degeneration (13) 13
endophthalmitis (13) 13
follow-up studies (13) 13
photochemotherapy (13) 13
retinopathy (13) 13
age (12) 12
cancer (12) 12
choroidal neovascularization secondary (12) 12
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (243) 243
French (5) 5
German (5) 5
Turkish (4) 4
Polish (3) 3
Czech (2) 2
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Ophthalmology, ISSN 1177-5467, 02/2015, Volume 9, pp. 323 - 335
Population pharmacokinetic modeling of pegaptanib was undertaken to determine influence of renal function on apparent clearance. In a randomized, double-masked... 
Population pharmacokinetics | Renal function | Clearance | Pegaptanib | Diabetic macular edema | Diabetic retinopathy | Patient outcomes | Drug metabolism | Eye diseases | Drug therapy | Observations | Macular degeneration | Studies | Edema | Sodium | Population | Diabetes | Permeability | Ophthalmology | Vascular endothelial growth factor | Drug dosages | Age | Creatinine | Extrapolation | Dosing | Mathematical models | Exposure | Clearances | Patients
Journal Article
Acta Ophthalmologica, ISSN 1755-375X, 09/2009, Volume 87, Issue 6, pp. 623 - 630
Journal Article
Retina, ISSN 0275-004X, 02/2013, Volume 33, Issue 2, pp. 397 - 402
Journal Article
Experimental and Therapeutic Medicine, ISSN 1792-0981, 12/2017, Volume 14, Issue 6, pp. 6002 - 6006
The aim of the present study was to report the importance of pegaptanib sodium (PGSD) injection treatment for vascular active vitreoretinopathy (VAVR). A total... 
Vascular active vitreoretinopathy | Visual acuity | Inflammation | Pegaptanib sodium | SURGERY | MEDICINE, RESEARCH & EXPERIMENTAL | vascular active vitreoretinopathy | visual acuity | MACUGEN | MACULAR DEGENERATION | pegaptanib sodium | LOCUS | TRACTION | THERAPY | inflammation | DISEASE | PROLIFERATIVE VITREORETINOPATHY | FAMILIAL EXUDATIVE VITREORETINOPATHY
Journal Article
Japanese Journal of Ophthalmology, ISSN 0021-5155, 9/2013, Volume 57, Issue 5, pp. 417 - 423
Journal Article
Journal Article